Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Neurology›Condition·Updated Jun 27, 2026·v1

Essential Tremor

Essential tremor is a prevalent, progressive kinetic tremor driven by cerebello‑thalamo‑cortical dysfunction. Diagnosis rests on a focused history, exam, and optional EMG/TSI; imaging is reserved for atypical cases or surgical planning. First‑line therapy with propranolol or primidone provides modest benefit, but most patients eventually require definitive intervention. MR‑guided focused ultrasound thalamotomy and VIM deep‑brain stimulation are evidence‑based, durable options that markedly reduce tremor severity and improve function. Adjunctive agents, botulinum toxin for voice tremor, and non‑invasive neuromodulation fill residual gaps. Early recognition of severe disease (CRST ≥ 32, ET‑plus features) and timely referral to a movement‑disorders specialist are essential to preserve independence and quality of life.

High Evidence152 references·1,396 words·6 min read·v1
neurologymovement disorderessential tremortremordeep brain stimulationfocused ultrasound

Quick Reference

RxDrug of choicePropranolol (40 mg PO BID → titrate to 240 mg/day) or Primidone (25 mg PO nightly → titrate to 750 mg/day) if β‑blocker contraindicated
AltAlternativesTopiramate 400 mg/day, Zonisamide 200 mg/day, Botulinum toxin A for voice tremor, cTBS for non‑invasive neuromodulation
⊘AvoidChronic high‑dose benzodiazepines, non‑selective β‑blockers in severe asthma/COPD, primidone in severe hepatic failure (AST/ALT >3×ULN)
DxTest of choiceClinical exam with CRST/TETRAS; surface EMG/TSI if diagnosis uncertain
ScKey scoreCRST total ≥32 (severe) or TETRAS ≥7 (moderate) triggers procedural referral
→When to referFailure of propranolol + primidone at maximal tolerated doses, CRST >32, emergence of ET‑plus signs, or patient preference for definitive therapy
Start β‑blocker or primidone; if tremor remains disabling (CRST ≥ 32) move quickly to MRgFUS thalamotomy or VIM DBS, and use adjunctive agents only for residual symptoms.
Essential tremor (ET) is the most common adult movement disorder, presenting as a chronic, action‑dominant kinetic tremor of the upper limbs that may spread to the head, voice, or lower limbs. It affects ~4‑5 % of adults over 65, progresses slowly, and can cause disabling functional impairment. Diagnosis is clinical, supported by targeted imaging and electrophysiology, while treatment ranges from β‑blockers to definitive surgical options.

Overview and Recommendations

Background

  • •Essential tremor (ET) is a chronic, action‑predominant kinetic tremor of ≥4 Hz that persists during voluntary movement, posture and intention, without other neurologic signs, and may involve the , voice and lower limbs.
  • •ET affects ~4 % of adults >65 y, making it the most prevalent adult movement disorder and a leading cause of disability in fine‑motor tasks such as writing, drinking and buttoning.
  • •Three overlapping taxonomic axes organize ET: (1) syndromic label (ET vs ET‑plus), (2) genetic/etiologic category (familial, sporadic, monogenic), and (3) neuroanatomic phenotype (cerebellar‑dominant, brain‑stem‑dominant).
  • •The cerebello‑thalamo‑cortical (CTC) loop is the core oscillator; Purkinje‑cell loss and dentate‑nucleus GABA‑receptor deficiency generate rhythmic output that is amplified by the ventral intermediate nucleus (VIM) and primary motor cortex.
  • •Family history multiplies risk 3‑5‑fold; common risk loci include rs3794087 in (OR 1.46) and rare FUS mutations, supporting a polygenic architecture with occasional monogenic contributors.
  • •Untreated ET progresses at ~0.5‑1.0 CRST points per year, with ~12 % developing dementia over 4 years, underscoring the need for early therapeutic intervention.

Evaluation

  • •Suspect ET when a patient reports bilateral hand tremor that worsens with posture or purposeful movement, improves with alcohol, and lacks resting tremor, rigidity or bradykinesia.
  • •Ask about age at onset, family history, caffeine intake, medication triggers (e.g., lithium, valproate), and the impact on activities of daily living (ADL) using the or .
  • •Examine for a 4‑12 Hz postural/kinetic tremor by having the patient extend the arms with palms down; note amplitude, symmetry and any aggravation with mental stress or caffeine.
  • •Screen for soft neurological signs (gait ataxia, mild dystonia) that would reclassify the patient as ET‑plus, as these predict faster functional decline.
  • •Order a non‑contrast of the brain only if atypical features are present (e.g., focal weakness, cerebellar signs) or when planning surgical therapy; normal MRI supports idiopathic ET.
  • •Obtain surface EMG with spectral analysis or a portable accelerometer to confirm a rhythmic 4‑12 Hz burst without co‑contraction; a Tremor Stability Index (TSI) ≥0.85 differentiates ET from dystonic tremor with >85 % accuracy.
  • •Perform a blink‑reflex test; a normal R2 recovery curve helps exclude Parkinsonian tremor, which shows an exaggerated R2 component.
  • •If the clinical picture remains ambiguous, consider to rule out dopaminergic deficit disorders; a normal scan reinforces the ET diagnosis.
  • •Document baseline CRST total score, TETRAS performance score, and MoCA; these values guide severity staging and future treatment thresholds.
  • •For patients being considered for procedural therapy, obtain baseline neuropsychological testing, audiometry and pulmonary function (FVC) to assess peri‑operative risk.
  • •When a patient presents with sudden worsening, obtain emergent CT/MRI to exclude stroke, intracranial hemorrhage, or peri‑lead edema if a DBS system is already implanted.
  • •If DBS hardware is present, interrogate the programmer for battery status, lead impedance and recent parameter changes before any imaging.
  • •Classify tremor severity at the bedside: mild (CRST <20), moderate (CRST 20‑32) or severe (CRST >32) to determine escalation pathways.

Management

  • •Initiate first‑line oral therapy with extended‑release 40 mg PO BID, titrating to 240 mg/day (max 80 mg BID) while monitoring heart rate, blood pressure and bronchospasm; aim for ≥50 % tremor reduction within 4 weeks.
  • •If β‑blocker contraindicated (asthma, severe bradycardia), start 25 mg PO nightly, increasing by 25 mg every 3‑4 days to a target of 750 mg/day (max 250 mg TID) while checking CBC and liver enzymes.
  • •For patients who fail or cannot tolerate propranolol + primidone, add second‑line agents: 25 mg PO BID, titrating to 400 mg/day; monitor serum bicarbonate and renal function.
  • •Consider off‑label 100 mg PO QD, titrating to 200 mg/day, only after discussion of limited efficacy and risk of metabolic acidosis.
  • •Avoid chronic benzodiazepines for tremor control; they provide transient relief but increase fall risk and sedation.
  • •When CRST total ≥32 or TETRAS ≥7 despite optimal oral therapy, refer for definitive procedural therapy (see below) and discontinue further dose escalation of oral agents.
  • •Offer unilateral MRI‑guided focused ultrasound (MRgFUS) thalamotomy of the VIM as first‑line definitive therapy: deliver acoustic energy up to 1,300 J, achieving a target temperature of 54‑60 °C for a 2‑3 mm lesion; this yields a mean 42 % tremor reduction at 12 months.
  • •If MRgFUS is contraindicated (e.g., skull‑density <0.3) or bilateral control is needed, proceed with bilateral VIM deep‑brain stimulation (DBS): program initially at 130 Hz, pulse width 60 µs, amplitude 2‑3 V, titrating every 1‑2 weeks to achieve ≥50 % tremor reduction.
  • •During DBS programming, use current‑steering and short‑pulse widths (≤60 µs) to minimize dysarthria and gait ataxia; re‑program if speech worsens or FVC falls below 50 % predicted.
  • •For refractory voice tremor, inject 2.5‑5 U per vocal fold every 3‑4 months; monitor for dysphagia and adjust dose accordingly.
  • •If surgical candidates decline invasive procedures, offer a trial of continuous theta‑burst stimulation (cTBS) to bilateral M1 and cerebellum (80 % AMT, 600 pulses per target); a single session can reduce FTM‑TRS scores by ~15 % within 45 minutes.
  • •Monitor tremor severity with CRST and TETRAS at 1 month, 3 months, then every 6 months; document adverse effects (hypotension, sedation, dysarthria) at each visit.
  • •Check renal function (eGFR) and electrolytes before each dose increase of primidone or zonisamide; reduce primidone to ≤100 mg/day if eGFR <30 ml/min/1.73 m².
  • •Screen for cognitive decline annually with MoCA; a score <26 may influence surgical candidacy and warrants neuropsychology referral.
  • •Educate patients to avoid excessive caffeine and to use moderate alcohol (≈20 g ethanol) only as a temporary test of cerebellar responsiveness, not as a chronic therapy.
  • •Do NOT prescribe high‑dose non‑selective β‑blockers (e.g., propranolol >240 mg/day) in the elderly with COPD or heart failure, as the risk of bronchospasm and decompensation outweighs modest tremor benefit.
  • •Refer to a movement‑disorders specialist when tremor is refractory after two adequate trials, when CRST >32, or when ET‑plus features emerge, to discuss procedural options and multidisciplinary rehabilitation.

Board Review — High Yield

  • •Essential tremor prevalence, ~4 % of adults >65 y, the most common adult movement disorder.
  • •Core oscillator, Cerebello‑thalamo‑cortical loop; dentate‑nucleus GABA loss drives rhythmic output.
  • •First‑line drugs, Propranolol (max 240 mg/day) or Primidone (max 750 mg/day).
  • •Surgical threshold, CRST total ≥32 or TETRAS ≥7 despite optimal meds → MRgFUS or DBS.
  • •MRgFUS outcome, ~42 % tremor reduction at 12 months with <5 % serious adverse events.
  • •DBS programming tip, Use short pulse width (≤60 µs) and current steering to avoid dysarthria.
  • •ET‑plus, Presence of soft signs (gait ataxia, mild dystonia) predicts faster functional decline.
  • •Voice tremor treatment, Botulinum toxin A 2.5‑5 U per vocal fold every 3‑4 months.
  • •Pregnancy, Prefer selective β1‑blocker atenolol 25 mg daily; avoid high‑dose propranolol.
  • •Elderly dosing, Propranolol 10 mg daily titrated to ≤80 mg/day; monitor for hypotension.

Deep Dive — Evidence Details

References

  1. [1]

    Barbe MT, Reker P, Hamacher S et al.. “DBS of the PSA and the VIM in essential tremor: A randomized, double-blind, crossover trial.” Neurology (2018). PMID: 29970404 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care
  2. [2]

    Halpern CH, Santini V, Lipsman N et al.. “Three-year follow-up of prospective trial of focused ultrasound thalamotomy for essential tremor.” Neurology (2019). PMID: 31748250 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Complications
  3. [3]

    Haubenberger D, McCrossin G, Lungu C et al.. “Octanoic acid in alcohol-responsive essential tremor: a randomized controlled study.” Neurology (2013). PMID: 23408867 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Prognosis & Natural History
  4. [4]

    Kuhlenbäumer G, Hopfner F, Deuschl G. “Genetics of essential tremor: meta-analysis and review.” Neurology (2014). PMID: 24532269 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification
  5. [5]

    Tsuboi T, Jabarkheel Z, Zeilman PR et al.. “Longitudinal follow-up with VIM thalamic deep brain stimulation for dystonic or essential tremor.” Neurology (2020). PMID: 32047071 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature
  6. [6]

    Fasano A, Llinas M, Munhoz RP et al.. “MRI-guided focused ultrasound thalamotomy in non-ET tremor syndromes.” Neurology (2017). PMID: 28747452 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature, Prognosis & Natural History
  7. [7]

    Donadio V, Incensi A, Rizzo G et al.. “Skin intraneural phosphorylated α-synuclein is a highly specific biomarker for early Parkinson's disease.” Brain : a journal of neurology (2026). PMID: 40920014 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification
  8. [8]

    di Biase L, Brittain JS, Shah SA et al.. “Tremor stability index: a new tool for differential diagnosis in tremor syndromes.” Brain : a journal of neurology (2017). PMID: 28459950 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification
  9. [9]

    Beason-Held LL, Kerley CI, Chaganti S et al.. “Health Conditions Associated with Alzheimer's Disease and Vascular Dementia.” Annals of neurology (2023). PMID: 36571386 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  10. [10]

    McGurrin P, Norato G, Thompson-Westra J et al.. “Objective response to ethanol in essential tremor: results from a standardized ethanol challenge study.” Annals of clinical and translational neurology (2023). PMID: 38087917 ↗

    L2TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature
  11. [11]

    Lin S, Gao C, Li H et al.. “Wearable sensor-based gait analysis to discriminate early Parkinson's disease from essential tremor.” Journal of neurology (2023). PMID: 36725698 ↗

    L2TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Clinical Presentation
  12. [12]

    Fathollahi MA, Khani Y, Bayati H et al.. “Performance of machine learning algorithms in diffusion tensor imaging of movement disorders: an exploratory meta-analysis.” Biomedical engineering online (2026). PMID: 41654900 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature
  13. [13]

    Caroppo A, Manni A, Rescio G et al.. “Movement Disorders and Smart Wrist Devices: A Comprehensive Study.” Sensors (Basel, Switzerland) (2025). PMID: 39797057 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature
  14. [14]

    van den Brandhof EL, van der Stouwe AMM, van der Veen S et al.. “Machine learning based EMG analysis of intermuscular coherence and cumulant density in tremor and myoclonus.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2026). PMID: 42288449 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  15. [15]

    Bayen AB, Choudhury S, Majumdar S et al.. “Machine Learning Aided Kinematic Profiling of Reaching Movements Separates Spinocerebellar Ataxia type 12 and Essential Tremor.” Cerebellum (London, England) (2026). PMID: 42274882 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature
  16. [16]

    Lorenz D, Hagen K, Ufer M et al.. “No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study.” Neurology (2006). PMID: 16769957 ↗

    L1RCTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification, Prognosis & Natural History
  17. [17]

    Louis ED, Bares M, Benito-Leon J et al.. “Essential tremor-plus: a controversial new concept.” The Lancet. Neurology (2019). PMID: 31767343 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation, Prognosis & Natural History
  18. [18]

    Louis ED. “Essential tremor: evolving clinicopathological concepts in an era of intensive post-mortem enquiry.” The Lancet. Neurology (2010). PMID: 20451458 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  19. [19]

    Hopfner F, Höglinger GU, Kuhlenbäumer G et al.. “β-adrenoreceptors and the risk of Parkinson's disease.” The Lancet. Neurology (2020). PMID: 31999942 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors
  20. [20]

    Shaikh AG, Miura K, Optican LM et al.. “A new familial disease of saccadic oscillations and limb tremor provides clues to mechanisms of common tremor disorders.” Brain : a journal of neurology (2007). PMID: 17921180 ↗

    L4CASE_REPORTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  21. [21]

    Dirkx MF, Zach H, Bloem BR et al.. “The nature of postural tremor in Parkinson disease.” Neurology (2018). PMID: 29476038 ↗

    L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  22. [22]

    Younger E, Ellis EG, Parsons N et al.. “Mapping Essential Tremor to a Common Brain Network Using Functional Connectivity Analysis.” Neurology (2023). PMID: 37596042 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification
  23. [23]

    Gillman A, Babij R, Lee M et al.. “Reflections: neurology and the humanities. Odd harvest.” Neurology (2014). PMID: 24571012 ↗

    L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  24. [24]

    Thier S, Lorenz D, Nothnagel M et al.. “Polymorphisms in the glial glutamate transporter SLC1A2 are associated with essential tremor.” Neurology (2012). PMID: 22764253 ↗

    L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Neurorehabilitation, Symptomatic & Supportive Care
  25. [25]

    Miocinovic S, Somayajula S, Chitnis S et al.. “History, applications, and mechanisms of deep brain stimulation.” JAMA neurology (2013). PMID: 23407652 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Prognosis & Natural History
  26. [26]

    Bi H, Wan Y, Zhao R et al.. “Intronic VNTRs downregulate expression of HSF1 and confer genetic risk of essential tremor.” Brain : a journal of neurology (2025). PMID: 40581632 ↗

    L4OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification
  27. [27]

    Tsuboi T, Wong JK, Eisinger RS et al.. “Comparative connectivity correlates of dystonic and essential tremor deep brain stimulation.” Brain : a journal of neurology (2021). PMID: 33889943 ↗

    L4OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification
  28. [28]

    Buijink AW, van der Stouwe AM, Broersma M et al.. “Motor network disruption in essential tremor: a functional and effective connectivity study.” Brain : a journal of neurology (2015). PMID: 26248468 ↗

    L4OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  29. [29]

    Paris-Robidas S, Brochu E, Sintes M et al.. “Defective dentate nucleus GABA receptors in essential tremor.” Brain : a journal of neurology (2011). PMID: 22120148 ↗

    L4OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  30. [30]

    Pedrosa DJ, Brown P, Cagnan H et al.. “A functional micro-electrode mapping of ventral thalamus in essential tremor.” Brain : a journal of neurology (2018). PMID: 30052807 ↗

    L4OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  31. [31]

    Zange L, Noack C, Hahn K et al.. “Phosphorylated α-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy.” Brain : a journal of neurology (2015). PMID: 26017579 ↗

    L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  32. [32]

    Milosevic L, Kalia SK, Hodaie M et al.. “Physiological mechanisms of thalamic ventral intermediate nucleus stimulation for tremor suppression.” Brain : a journal of neurology (2018). PMID: 29878147 ↗

    L4OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  33. [33]

    van der Linden C, Berger T, Dembek TA et al.. “Tractography-guided versus clinical contact selection for deep brain stimulation in tremor - A prospective clinical trial.” Brain stimulation (2026). PMID: 41740836 ↗

    L2TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification, Prognosis & Natural History
  34. [34]

    Zhang L, Cui S, Bi H et al.. “The research focus and frontiers in surgical treatment of essential tremor.” Frontiers in neurology (2024). PMID: 39722689 ↗

    L5SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  35. [35]

    Asahi T, Nonaka T, Asahi T et al.. “Lack of Therapeutic Benefit of Ventral Intermediate Nucleus Thalamotomy for Tremor-Like Myoclonus in Two Cases of Benign Adult Familial Myoclonus Epilepsy.” Stereotactic and functional neurosurgery (2025). PMID: 40349691 ↗

    L4CASE_REPORTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  36. [36]

    Chen Z, Yao J, Lin J et al.. “Exploring Risk Drugs and Mechanisms in Dystonia: Insights from Pharmacovigilance and Proteogenomics.” Current neuropharmacology (2026). PMID: 42051091 ↗

    L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors
  37. [37]

    Scott T, Ricciardi L, Hart MG et al.. “Between Surgery and Science: Patient Journeys in Deep Brain Stimulation Local Field Potential Research.” Neuromodulation : journal of the International Neuromodulation Society (2026). PMID: 41910515 ↗

    L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  38. [38]

    Wan J, Pan H, Chang D et al.. “The genetic spectrum of LRRK2 variants in Parkinson's disease: findings from a large Chinese cohort.” NPJ Parkinson's disease (2026). PMID: 41904258 ↗

    L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  39. [39]

    Darcourt J, Koulibaly PM, Schiazza A et al.. “Assessment of striatal and extrastriatal [18F]fluoroDOPA uptake by a Silicon Photomultiplier PET camera in Parkinson's disease.” EJNMMI research (2026). PMID: 41781550 ↗

    L4OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  40. [40]

    Petramfar P, Jankovic J. “Yawning-related tremor in patients with Parkinson's disease.” Parkinsonism & related disorders (2025). PMID: 41443029 ↗

    L4OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  41. [41]

    Alonso-Navarro H, García-Martín E, Agúndez JAG et al.. “Association between restless legs syndrome and other movement disorders.” Neurology (2019). PMID: 31004074 ↗

    L3SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  42. [42]

    Liao C, Castonguay CE, Heilbron K et al.. “Association of Essential Tremor With Novel Risk Loci: A Genome-Wide Association Study and Meta-analysis.” JAMA neurology (2022). PMID: 34982113 ↗

    L3SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  43. [43]

    Louis ED, Benito-León J, Bermejo-Pareja F. “Population-based prospective study of cigarette smoking and risk of incident essential tremor.” Neurology (2008). PMID: 18458228 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors
  44. [44]

    Shaikh AG, Fasano A, Pandey S et al.. “Challenges in Describing Tremor and Dystonia.” Neurology (2024). PMID: 39724539 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  45. [45]

    Defazio G, Conte A, Gigante AF et al.. “Is tremor in dystonia a phenotypic feature of dystonia?” Neurology (2015). PMID: 25663232 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  46. [46]

    Shill HA, Adler CH, Sabbagh MN et al.. “Pathologic findings in prospectively ascertained essential tremor subjects.” Neurology (2008). PMID: 18413570 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  47. [47]

    Wu YR, Foo JN, Tan LC et al.. “Identification of a novel risk variant in the FUS gene in essential tremor.” Neurology (2013). PMID: 23825177 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors
  48. [48]

    Louis ED, Benito-León J, Ottman R et al.. “A population-based study of mortality in essential tremor.” Neurology (2007). PMID: 18025392 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications
  49. [49]

    Baykan B, Franceschetti S, Canafoglia L et al.. “Differential diagnosis of familial adult myoclonic epilepsy.” Epilepsia (2023). PMID: 36751956 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Complications
  50. [50]

    Lu Y, Ge Y, Wang R et al.. “Familial adult myoclonus epilepsy: A comprehensive diagnostic strategy for clinical practice.” Epilepsia (2025). PMID: 40747611 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  51. [51]

    Deng H, Le W, Jankovic J. “Genetics of essential tremor.” Brain : a journal of neurology (2007). PMID: 17353225 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  52. [52]

    DeSimone JC, Archer DB, Vaillancourt DE et al.. “Network-level connectivity is a critical feature distinguishing dystonic tremor and essential tremor.” Brain : a journal of neurology (2019). PMID: 30957839 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
  53. [53]

    Segar DJ, Lak AM, Lee S et al.. “Lesion location and lesion creation affect outcomes after focused ultrasound thalamotomy.” Brain : a journal of neurology (2021). PMID: 34750621 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors
  54. [54]

    Sun QY, Xu Q, Tian Y et al.. “Expansion of GGC repeat in the human-specific NOTCH2NLC gene is associated with essential tremor.” Brain : a journal of neurology (2020). PMID: 31819945 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors
  55. [55]

    Ghanem A, Berry DS, Burkes A et al.. “Prevalence of and Annual Conversion Rates to Mild Cognitive Impairment and Dementia: Prospective, Longitudinal Study of an Essential Tremor Cohort.” Annals of neurology (2024). PMID: 38654628 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications
  56. [56]

    Balduino de Souza AL, Mendes TP, Rocha Dos Santos MA et al.. “Safety of Focused Ultrasound Ablation in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 40058246 ↗

    L1SR_MA_RCTCited in: Epidemiology, Etiology & Risk Factors, Complications
  57. [57]

    Louis ED. “The Association Between Essential Tremor and Parkinson's Disease: A Systematic Review of Clinical and Epidemiological Studies.” Journal of clinical medicine (2025). PMID: 40283467 ↗

    L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  58. [58]

    Nguyen TTH, Fournier A, Courtois É et al.. “Use of β-adrenoreceptor drugs and Parkinson's disease incidence in women from the French E3N cohort study.” Journal of Parkinson's disease (2025). PMID: 40302366 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors
  59. [59]

    Louis ED, Sharma VD, Wainman E et al.. “How Well Do Essential Tremor Patients Report whether or Not They Have Parkinson's Disease? Validity of Self-Report Data from a Large Cohort Study.” Neuroepidemiology (2025). PMID: 40288369 ↗

    L4COHORTCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Prevention
  60. [60]

    Shi Q, Han J, Chen B et al.. “Comparative Efficacy of Acupuncture Therapy in Primary Essential Tremor: A Network Meta-Analysis and Systematic Review.” Healthcare (Basel, Switzerland) (2026). PMID: 41897256 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  61. [61]

    Chintapalli R, Chang S, Kaprealian T et al.. “Gamma knife versus linear accelerator thalamotomy for essential tremor and Parkinson's disease: A systematic review and meta-analysis.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 39823912 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  62. [62]

    Li Y, He R, Li M et al.. “Higher Prevalence of Common Neurological Soft Signs in Essential Tremor With Midline Distribution: A Multicenter Cohort Study.” Journal of clinical neurology (Seoul, Korea) (2025). PMID: 40065450 ↗

    L4COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
  63. [63]

    Benito-León J, Louis ED, Bermejo-Pareja F. “Population-based case-control study of cognitive function in essential tremor.” Neurology (2006). PMID: 16401849 ↗

    L3CASE_CONTROLCited in: Clinical Presentation
  64. [64]

    Tolosa E, Wenning G, Poewe W. “The diagnosis of Parkinson's disease.” The Lancet. Neurology (2006). PMID: 16361025 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  65. [65]

    Nisticò R, Pirritano D, Novellino F et al.. “Blink reflex recovery cycle in patients with essential tremor associated with resting tremor.” Neurology (2012). PMID: 22993289 ↗

    L4OTHERCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  66. [66]

    Cummings JL, Henchcliffe C, Schaier S et al.. “The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration.” Brain : a journal of neurology (2011). PMID: 21810889 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History
  67. [67]

    Klostermann F, Wahl M, Marzinzik F et al.. “Mental chronometry of target detection: human thalamus leads cortex.” Brain : a journal of neurology (2006). PMID: 16418179 ↗

    L4OTHERCited in: Clinical Presentation
  68. [68]

    Berry DS, Cosentino S, Louis ED. “A prospective cohort study of familial versus sporadic essential tremor cases: Do clinical features evolve differently across time?” Journal of the neurological sciences (2023). PMID: 37924593 ↗

    L2COHORTCited in: Clinical Presentation
  69. [69]

    Vetkas A, Yang A, Boutet A et al.. “One Side or Two? A Systematic Review of Deep Brain Stimulation Approaches in Movement Disorders.” Movement disorders clinical practice (2025). PMID: 40810258 ↗

    L5SR_OBSCited in: Clinical Presentation
  70. [70]

    Dhar D, Kamble N, Pal PK. “Long Latency Reflexes in Clinical Neurology: A Systematic Review.” The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques (2022). PMID: 35801267 ↗

    L5SR_OBSCited in: Clinical Presentation
  71. [71]

    Swackhamer HP, Stoica S, Sapkota M et al.. “Diagnostic performance of essential tremor criteria in electronic health records: a retrospective neurology cohort study.” Frontiers in neurology (2026). PMID: 41743048 ↗

    L3COHORTCited in: Clinical Presentation
  72. [72]

    Favi Bocca L, Davidson B, Lam B et al.. “Successful MRgFUS VIM Thalamotomy for essential tremor nearby cavernous malformation: image case report.” Stereotactic and functional neurosurgery (2026). PMID: 42348493 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  73. [73]

    Elias WJ, Lipsman N, Ondo WG et al.. “A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor.” The New England journal of medicine (2016). PMID: 27557301 ↗

    L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Neurorehabilitation, Symptomatic & Supportive Care, Complications, Prognosis & Natural History
  74. [74]

    Ondo WG, Lv W, Zhu X et al.. “Transcutaneous Peripheral Nerve Stimulation for Essential Tremor: A Randomized Clinical Trial.” JAMA neurology (2025). PMID: 41114984 ↗

    L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Prognosis & Natural History
  75. [75]

    Elias WJ, Huss D, Voss T et al.. “A pilot study of focused ultrasound thalamotomy for essential tremor.” The New England journal of medicine (2013). PMID: 23944301 ↗

    L4TRIAL_NONRANDOMCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Complications, Prognosis & Natural History
  76. [76]

    Kaplitt MG, Krishna V, Eisenberg HM et al.. “Safety and Efficacy of Staged, Bilateral Focused Ultrasound Thalamotomy in Essential Tremor: An Open-Label Clinical Trial.” JAMA neurology (2024). PMID: 39073822 ↗

    L4TRIAL_NONRANDOMCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
  77. [77]

    Deuschl G, Raethjen J, Hellriegel H et al.. “Treatment of patients with essential tremor.” The Lancet. Neurology (2011). PMID: 21256454 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Prognosis & Natural History
  78. [78]

    Hassan A, Ahlskog JE, Matsumoto JY et al.. “Orthostatic tremor: Clinical, electrophysiologic, and treatment findings in 184 patients.” Neurology (2016). PMID: 26747880 ↗

    L4OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prognosis & Natural History
  79. [79]

    Tinazzi M, Fasano A, Di Matteo A et al.. “Temporal discrimination in patients with dystonia and tremor and patients with essential tremor.” Neurology (2012). PMID: 23243072 ↗

    L3OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  80. [80]

    Nicoletti G, Manners D, Novellino F et al.. “Diffusion tensor MRI changes in cerebellar structures of patients with familial essential tremor.” Neurology (2010). PMID: 20308683 ↗

    L3OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  81. [81]

    Bowen LN, Malaty IA, Rodriguez RL et al.. “Did General Douglas MacArthur have Parkinson disease? A video and archival analysis.” Neurology (2011). PMID: 21555736 ↗

    L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  82. [82]

    Krishna V, Sammartino F, Rezai A. “A Review of the Current Therapies, Challenges, and Future Directions of Transcranial Focused Ultrasound Technology: Advances in Diagnosis and Treatment.” JAMA neurology (2018). PMID: 29228074 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Neurorehabilitation, Symptomatic & Supportive Care
  83. [83]

    Boutet A, Ranjan M, Zhong J et al.. “Focused ultrasound thalamotomy location determines clinical benefits in patients with essential tremor.” Brain : a journal of neurology (2018). PMID: 30452554 ↗

    L4OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Complications
  84. [84]

    Gibson WS, Jo HJ, Testini P et al.. “Functional correlates of the therapeutic and adverse effects evoked by thalamic stimulation for essential tremor.” Brain : a journal of neurology (2016). PMID: 27329768 ↗

    L4OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Complications
  85. [85]

    Shi CH, Fan Y, Yang J et al.. “NOTCH2NLC Intermediate-Length Repeat Expansions Are Associated with Parkinson Disease.” Annals of neurology (2020). PMID: 33016348 ↗

    L3OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  86. [86]

    Louis ED, Hernandez NC, Guy T et al.. “The Relationship between Rest Tremor and Underlying Lewy Pathology in Essential Tremor: A Clinical-Pathological Study of 201 Cases.” Annals of neurology (2025). PMID: 40521765 ↗

    L4OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification
  87. [87]

    Theyer C, Kirchmair J, Jagusch F et al.. “The Utility of Olfactory Testing to Discriminate Parkinson's Disease From Diagnostic Mimics: A Systematic Review and Meta-Analysis.” European journal of neurology (2026). PMID: 41467596 ↗

    L1SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  88. [88]

    Shih LC. “Essential Tremor.” Continuum (Minneapolis, Minn.) (2025). PMID: 40748121 ↗

    L5CASE_REPORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  89. [89]

    Stiehm M, Nilsson C, Skogar Ö et al.. “The diagnostic value of transcranial sonography in Swedish parkinsonism patients: A retrospective cohort study with long-term follow-up.” Clinical parkinsonism & related disorders (2025). PMID: 41479687 ↗

    L3COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  90. [90]

    Lavalley A, Lorton O, Constanthin P et al.. “A Fully MRI-Compatible, Non-Electrical System for Near Real-Time Tremor Monitoring During MR-guided Focused Ultrasound.” Stereotactic and functional neurosurgery (2026). PMID: 42360978 ↗

    L4OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  91. [91]

    Shalem N, Sinai A, Zur G et al.. “Personalized tremor control targeting for MR-guided focused ultrasound using tractography.” Brain communications (2026). PMID: 42339154 ↗

    L4OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  92. [92]

    Wójcik-Pędziwiatr M, Rudzińska-Bar M. “Pace-Induced Saccades in Essential Tremor Differ from Those in Parkinson's Disease and Degenerative Ataxias.” Journal of clinical medicine (2026). PMID: 42278915 ↗

    L3OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  93. [93]

    Silva NA, Hernandez A, Dwivedi AK et al.. “Exploring the Patient Pathway to Focused Ultrasound Ablation for Essential Tremor: A Mixed-Method Approach.” Stereotactic and functional neurosurgery (2026). PMID: 42275264 ↗

    L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  94. [94]

    Kumar A, Kuo SH. “Investigating Cerebello-Cortical Networks With EEG: Advances and Future Challenges.” Cerebellum (London, England) (2026). PMID: 42234314 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  95. [95]

    Ondo WG, Jankovic J, Connor GS et al.. “Topiramate in essential tremor: a double-blind, placebo-controlled trial.” Neurology (2006). PMID: 16436648 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, Prognosis & Natural History
  96. [96]

    Bond AE, Shah BB, Huss DS et al.. “Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease: A Randomized Clinical Trial.” JAMA neurology (2017). PMID: 29084313 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
  97. [97]

    Chang JW, Park CK, Lipsman N et al.. “A prospective trial of magnetic resonance-guided focused ultrasound thalamotomy for essential tremor: Results at the 2-year follow-up.” Annals of neurology (2018). PMID: 29265546 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Complications, Prognosis & Natural History
  98. [98]

    Lipsman N, Schwartz ML, Huang Y et al.. “MR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study.” The Lancet. Neurology (2013). PMID: 23523144 ↗

    L4OTHERCited in: Severity, Staging & Risk Stratification, Prognosis & Natural History
  99. [99]

    Wainman E, Berry DS, Hernandez NC et al.. “Neuropathologic Changes in People With Essential Tremor With Dementia: A Postmortem Study.” Neurology (2025). PMID: 41160795 ↗

    L4OTHERCited in: Severity, Staging & Risk Stratification
  100. [100]

    Vuong MQ, Sreenivasan V, Lee S et al.. “Low-intensity transcranial ultrasound effects on the ventral intermediate nucleus and zona incerta in Parkinson's disease tremor.” Brain stimulation (2026). PMID: 41519465 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification
  101. [101]

    Luo A, Huang H, Feng J et al.. “Acute effects of a single session of multitarget continuous Theta-Burst stimulation for essential Tremor: A Randomized, Sham-Controlled trial.” NeuroImage. Clinical (2025). PMID: 41319505 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History
  102. [102]

    Mohapatra P, Kumar Srivastava A, Garg D et al.. “Propranolol for Tremors in Spinocerebellar Ataxia Type 12: A Randomized Clinical Trial.” Movement disorders : official journal of the Movement Disorder Society (2025). PMID: 41261874 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Neurorehabilitation, Symptomatic & Supportive Care, Complications, Prognosis & Natural History
  103. [103]

    Gallea C, Popa T, García-Lorenzo D et al.. “Intrinsic signature of essential tremor in the cerebello-frontal network.” Brain : a journal of neurology (2015). PMID: 26115677 ↗

    L5OTHERCited in: Severity, Staging & Risk Stratification
  104. [104]

    Cagnan H, Little S, Foltynie T et al.. “The nature of tremor circuits in parkinsonian and essential tremor.” Brain : a journal of neurology (2014). PMID: 25200741 ↗

    L5OTHERCited in: Severity, Staging & Risk Stratification, Prognosis & Natural History
  105. [105]

    Groppa S, Herzog J, Falk D et al.. “Physiological and anatomical decomposition of subthalamic neurostimulation effects in essential tremor.” Brain : a journal of neurology (2013). PMID: 24277721 ↗

    L5OTHERCited in: Severity, Staging & Risk Stratification, Prognosis & Natural History
  106. [106]

    Kuo SH, Lin CY, Wang J et al.. “Deep brain stimulation and climbing fiber synaptic pathology in essential tremor.” Annals of neurology (2016). PMID: 27422481 ↗

    L5OTHERCited in: Severity, Staging & Risk Stratification
  107. [107]

    Tripoliti E, Tsuboi T, Barbe MT et al.. “Speech and Deep Brain Stimulation in Parkinson's Disease, Essential Tremor, and Dystonia: A Systematic Review and Meta-analysis.” Movement disorders : official journal of the Movement Disorder Society (2026). PMID: 42059110 ↗

    L2SR_OBSCited in: Severity, Staging & Risk Stratification, Special Populations & Prevention
  108. [108]

    Paio F, Ricciardi GK, Bulgarelli G et al.. “Staged Bilateral Magnetic Resonance-Guided Focused Ultrasound Thalamotomy for Essential Tremor: Prospective Single-Centre Cohort and Systematic Review With Meta-Analysis.” European journal of neurology (2026). PMID: 41914664 ↗

    L2SR_OBSCited in: Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
  109. [109]

    Sabet H, Abbas A, Salama EY et al.. “Deep brain stimulation and magnetic resonance-guided focused ultrasound for essential tremor: a meta-analysis of effectiveness and safety.” Neurosurgical review (2026). PMID: 41801476 ↗

    L2SR_OBSCited in: Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Complications, Prognosis & Natural History
  110. [110]

    Park YS, Kim Jp, Chang WS et al.. “Management of a DBS system in patients with traumatic brain injury: case report.” Neuromodulation : journal of the International Neuromodulation Society (2011). PMID: 21992242 ↗

    L4CASE_REPORTCited in: Acute Management & Time-Critical Pathway
  111. [111]

    Dandekar MP, Fenoy AJ, Carvalho AF et al.. “Deep brain stimulation for treatment-resistant depression: an integrative review of preclinical and clinical findings and translational implications.” Molecular psychiatry (2018). PMID: 29483673 ↗

    L5REVIEW_NARRATIVECited in: Acute Management & Time-Critical Pathway
  112. [112]

    Gironell A, Kulisevsky J. “Diagnosis and management of essential tremor and dystonic tremor.” Therapeutic advances in neurological disorders (2009). PMID: 21179530 ↗

    L5OTHERCited in: Acute Management & Time-Critical Pathway
  113. [113]

    Veilleux Carpentier A, Chan JL, Wong JK et al.. “An Eye on the First Surgical Side: Appreciating the Potential Impacts of a Second DBS Lead on Ipsilateral Symptoms.” Tremor and other hyperkinetic movements (New York, N.Y.) (2024). PMID: 38973819 ↗

    L4CASE_REPORTCited in: Acute Management & Time-Critical Pathway
  114. [114]

    Song L, Ma D, Zhang H et al.. “Disappearance of bilateral essential tremor after acute stroke: A case report and literature review.” Medicine (2026). PMID: 41578594 ↗

    L4CASE_REPORTCited in: Acute Management & Time-Critical Pathway
  115. [115]

    Manis MM, Petersen K, Roberts MZ et al.. “Managing the Drug-Drug Interaction With Apixaban and Primidone: A Case Report.” Hospital pharmacy (2023). PMID: 37360203 ↗

    L4CASE_REPORTCited in: Acute Management & Time-Critical Pathway
  116. [116]

    Nickl R, Fricke P, Capetian P et al.. “Acute postoperative anarthria following bilateral ventral intermediate nucleus deep brain stimulation: a rare presentation of early peri-lead edema. Illustrative case.” Journal of neurosurgery. Case lessons (2026). PMID: 42114167 ↗

    L5OTHERCited in: Acute Management & Time-Critical Pathway
  117. [117]

    Schreglmann SR, Bauer R, Hägele-Link S et al.. “Unilateral cerebellothalamic tract ablation in essential tremor by MRI-guided focused ultrasound.” Neurology (2017). PMID: 28275083 ↗

    L5OTHERCited in: Long-term & Definitive Management (Evidence Ladder), Neurorehabilitation, Symptomatic & Supportive Care, Complications
  118. [118]

    Mulder MB, Busschbach JJ, van Hoek B et al.. “Tremors and Health-Related Quality of Life in Liver Transplant Recipients: Post-hoc Analysis of a Multicenter, Randomized, Controlled Trial Comparing a Life Cycle Pharma-Tacrolimus Regimen and Extended-Release Tacrolimus Regimen.” Transplant international : official journal of the European Society for Organ Transplantation (2025). PMID: 40357166 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), Neurorehabilitation, Symptomatic & Supportive Care
  119. [119]

    Shin HW, Hallett M, Sohn YH. “Cerebellar repetitive transcranial magnetic stimulation for patients with essential tremor.” Parkinsonism & related disorders (2019). PMID: 30928207 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  120. [120]

    Poologaindran A, Ivanishvili Z, Morrison MD et al.. “The effect of unilateral thalamic deep brain stimulation on the vocal dysfunction in a patient with spasmodic dysphonia: interrogating cerebellar and pallidal neural circuits.” Journal of neurosurgery (2017). PMID: 28304188 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  121. [121]

    Akbar U, Raike RS, Hack N et al.. “Randomized, Blinded Pilot Testing of Nonconventional Stimulation Patterns and Shapes in Parkinson's Disease and Essential Tremor: Evidence for Further Evaluating Narrow and Biphasic Pulses.” Neuromodulation : journal of the International Neuromodulation Society (2016). PMID: 27000764 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  122. [122]

    Schuurman PR, Bosch DA, Merkus MP et al.. “Long-term follow-up of thalamic stimulation versus thalamotomy for tremor suppression.” Movement disorders : official journal of the Movement Disorder Society (2008). PMID: 18442104 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  123. [123]

    Zesiewicz TA, Ward CL, Hauser RA et al.. “A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.” Movement disorders : official journal of the Movement Disorder Society (2007). PMID: 17149715 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  124. [124]

    Jung NY, Park CK, Kim M et al.. “The efficacy and limits of magnetic resonance-guided focused ultrasound pallidotomy for Parkinson's disease: a Phase I clinical trial.” Journal of neurosurgery (2018). PMID: 30095337 ↗

    L2TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder)
  125. [125]

    Estes C, Sadoughi B, Coleman R et al.. “A prospective crossover trial of botulinum toxin chemodenervation versus injection augmentation for essential voice tremor.” The Laryngoscope (2017). PMID: 28988441 ↗

    L2TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder)
  126. [126]

    Klein JC, Barbe MT, Seifried C et al.. “The tremor network targeted by successful VIM deep brain stimulation in humans.” Neurology (2012). PMID: 22377809 ↗

    L4OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
  127. [127]

    Nagaratnam SA, Wilson D, Chiang HL et al.. “A Randomized, Double-Blind, Placebo Controlled, Crossover Trial of incobotulinumtoxinA Treatment for Upper Limb Tremor.” Movement disorders clinical practice (2025). PMID: 40276891 ↗

    L1RCTCited in: Neurorehabilitation, Symptomatic & Supportive Care, Complications
  128. [128]

    Aghajanian S, Naeimi A, Mohammadifard F et al.. “Comparative efficacy of PSA and VIM deep brain stimulation in essential tremor: a network and multilevel meta-analysis.” Neurosurgical review (2025). PMID: 41160184 ↗

    L5SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
  129. [129]

    Rabe YJC, Yu AB, Yu JRT et al.. “Effectiveness, safety, and quality of life outcomes of neurotoxin injections in the treatment of essential tremors: a systematic review.” Journal of neural transmission (Vienna, Austria : 1996) (2025). PMID: 41051546 ↗

    L5SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care, Complications
  130. [130]

    Barbe MT, Dembek TA, Becker J et al.. “Individualized current-shaping reduces DBS-induced dysarthria in patients with essential tremor.” Neurology (2014). PMID: 24443448 ↗

    L4OTHERCited in: Complications
  131. [131]

    Choe CU, Hidding U, Schaper M et al.. “Thalamic short pulse stimulation diminishes adverse effects in essential tremor patients.” Neurology (2018). PMID: 30045955 ↗

    L4OTHERCited in: Complications
  132. [132]

    Fasano A, Herzog J, Raethjen J et al.. “Gait ataxia in essential tremor is differentially modulated by thalamic stimulation.” Brain : a journal of neurology (2010). PMID: 20926368 ↗

    L4OTHERCited in: Complications
  133. [133]

    Deng H, Huang X, Wang Q et al.. “The Role of Biological Effective Dose in Gamma Knife Radiosurgery: A Systematic Review Across Multiple Indications.” Journal of clinical medicine (2026). PMID: 41517630 ↗

    L5SR_OBSCited in: Complications
  134. [134]

    Monteiro JDS, de Oliveira RR, Gonçalves OR et al.. “Magnetic resonance-guided focused ultrasound for essential tremor patients with low skull density ratio: A systematic review and meta-analysis.” Parkinsonism & related disorders (2025). PMID: 40617709 ↗

    L5SR_OBSCited in: Complications
  135. [135]

    Moro E, Schwalb JM, Piboolnurak P et al.. “Unilateral subdural motor cortex stimulation improves essential tremor but not Parkinson's disease.” Brain : a journal of neurology (2011). PMID: 21646329 ↗

    L4RCTCited in: Prognosis & Natural History
  136. [136]

    Simpson DM, Blitzer A, Brashear A et al.. “Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review) [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.” Neurology (2008). PMID: 18458230 ↗

    L5SR_OBSCited in: Prognosis & Natural History
  137. [137]

    Cury RG, Fraix V, Castrioto A et al.. “Thalamic deep brain stimulation for tremor in Parkinson disease, essential tremor, and dystonia.” Neurology (2017). PMID: 28768840 ↗

    L4OTHERCited in: Prognosis & Natural History
  138. [138]

    Al-Fatly B, Ewert S, Kübler D et al.. “Connectivity profile of thalamic deep brain stimulation to effectively treat essential tremor.” Brain : a journal of neurology (2019). PMID: 31377766 ↗

    L4OTHERCited in: Prognosis & Natural History
  139. [139]

    Favilla CG, Ullman D, Wagle Shukla A et al.. “Worsening essential tremor following deep brain stimulation: disease progression versus tolerance.” Brain : a journal of neurology (2012). PMID: 22344584 ↗

    L4OTHERCited in: Prognosis & Natural History
  140. [140]

    Cagnan H, Brittain JS, Little S et al.. “Phase dependent modulation of tremor amplitude in essential tremor through thalamic stimulation.” Brain : a journal of neurology (2013). PMID: 24038075 ↗

    L4OTHERCited in: Prognosis & Natural History
  141. [141]

    Neudorfer C, Kroneberg D, Al-Fatly B et al.. “Personalizing Deep Brain Stimulation Using Advanced Imaging Sequences.” Annals of neurology (2022). PMID: 35165921 ↗

    L4OTHERCited in: Prognosis & Natural History
  142. [142]

    Nowacki A, Barlatey S, Al-Fatly B et al.. “Probabilistic Mapping Reveals Optimal Stimulation Site in Essential Tremor.” Annals of neurology (2022). PMID: 35150172 ↗

    L4OTHERCited in: Prognosis & Natural History
  143. [143]

    Webb AJ, Fischer U, Rothwell PM. “Effects of β-blocker selectivity on blood pressure variability and stroke: a systematic review.” Neurology (2011). PMID: 21795649 ↗

    L5SR_OBSCited in: Special Populations & Prevention
  144. [144]

    Benito-León J, Louis ED, Bermejo-Pareja F. “Elderly-onset essential tremor is associated with dementia.” Neurology (2006). PMID: 16717208 ↗

    L3OTHERCited in: Special Populations & Prevention
  145. [145]

    Shatunov A, Sambuughin N, Jankovic J et al.. “Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23.” Brain : a journal of neurology (2006). PMID: 16702189 ↗

    L4OTHERCited in: Special Populations & Prevention
  146. [146]

    Song P, Zhang Y, Zha M et al.. “The global prevalence of essential tremor, with emphasis on age and sex: A meta-analysis.” Journal of global health (2021). PMID: 33880180 ↗

    L5SR_OBSCited in: Special Populations & Prevention
  147. [147]

    Berry DS, Nguyen D, Cosentino S et al.. “Associations between cognitive function and a range of significant life events in an elderly essential tremor cohort study.” Journal of the neurological sciences (2023). PMID: 37196573 ↗

    L2COHORTCited in: Special Populations & Prevention
  148. [148]

    Nabizadeh F, Aarabi MH. “Functional and structural lesion network mapping in neurological and psychiatric disorders: a systematic review.” Frontiers in neurology (2023). PMID: 37456650 ↗

    L5SR_OBSCited in: Special Populations & Prevention
  149. [149]

    Homann CN, Homann B, Ivanic G et al.. “Accidental Falls in Patients with Hyperkinetic Movement Disorders: A Systematic Review.” Tremor and other hyperkinetic movements (New York, N.Y.) (2022). PMID: 36303814 ↗

    L5SR_OBSCited in: Special Populations & Prevention
  150. [150]

    Gerbasi ME, Nambiar S, Reed S et al.. “Essential tremor patients experience significant burden beyond tremor: A systematic literature review.” Frontiers in neurology (2022). PMID: 35937052 ↗

    L5SR_OBSCited in: Special Populations & Prevention
  151. [151]

    Gerbasi ME, Eldar-Lissai A, Lyons KE. “Epidemiology of Pediatric Essential Tremor in the United States: A Systematic Literature Review from 2010 to 2020.” Tremor and other hyperkinetic movements (New York, N.Y.) (2022). PMID: 35531121 ↗

    L2SR_OBSCited in: Special Populations & Prevention
  152. [152]

    Boccia VD, Bellini G, Mogilner A et al.. “Safety and Efficacy of Focused Ultrasound Thalamotomy in Elderly Patients: A Single-Center Cohort Study.” Movement disorders clinical practice (2026). PMID: 41952374 ↗

    L3COHORTCited in: Special Populations & Prevention

Revision History

All updates applied to this page

Loading revisions…